National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1

Autor: Steve R. Feldman, Joel M. Gelfand, Christoph T. Ellebrecht, Erica J. Weinstein, Cassandra Calabrese, Joseph F. Merola, Dafna D. Gladman, George Gondo, Jose U. Scher, Vincent Lo Re, Mark Lebwohl, Maha N. Syed, George L. Anesi, April Armstrong, Jessica Smith, Andrew Blauvelt, Sergio Schwartzman, Anthony Ocon, Justine Fenner, James R. Treat, Christopher T. Ritchlin, Leon H Kircik, Stacie Bell, George R. Martin, Erica D. Dommasch, Sue Heydon, Abby S. Van Voorhees, Samantha Koons
Rok vydání: 2020
Předmět:
Delphi Technique
Epidemiology
Organizations
Nonprofit
Delphi method
Disease
IBD
Inflammatory Bowel Disease
030207 dermatology & venereal diseases
NIH
National Institutes of Health
0302 clinical medicine
Pandemic
Infectious Disease Medicine
COVID-19
Coronavirus disease 2019
TF
Task Force
HR
Hazards Ratio
Foundation (evidence)
IQR
Inter Quartile Range
SD
Standard Deviation
NPF
National Psoriasis Foundation
Psoriatic arthritis
030220 oncology & carcinogenesis
PsA
Psoriatic Arthritis
SARS COV-2
Severe Acute Respiratory Coronavirus 2
Coronavirus Infections
Immunosuppressive Agents
medicine.medical_specialty
Consensus
Critical Care
education
Advisory Committees
Pneumonia
Viral
Dermatology
Biologics
Article
WHO
World Health Organization
Betacoronavirus
03 medical and health sciences
Rheumatology
Psoriasis
medicine
Humans
CDC
Centers for Disease Control
Pandemics
IL
InterLeukin
SARS-CoV-2
business.industry
COVID-19
medicine.disease
FDA
Food and Drug Administration
United States
Living document
Family medicine
TNF
Tumor Necrosis Factor
JAK inhibitor
Janus Kinase Inhibitor
business
Zdroj: Journal of the American Academy of Dermatology
ISSN: 0190-9622
DOI: 10.1016/j.jaad.2020.09.001
Popis: Objective To provide guidance about management of psoriatic disease during the COVID-19 pandemic. Study Design A task force (TF) of 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical care was convened. The TF was supplemented by non-voting members which included fellows and National Psoriasis Foundation (NPF) staff. Clinical questions relevant to the psoriatic disease community were informed by questions received by the NPF. A Delphi process was conducted. Results The TF approved 22 guidance statements. The average of the votes was within the category of agreement for all statements. All guidance statements proposed were recommended, 9 with high consensus, 13 with moderate consensus. Limitations The evidence behind many guidance statements is limited in quality. Conclusion These statements provide guidance for the management of patients with psoriatic disease on topics ranging from how the disease and its treatments impact COVID-19 risk and outcome, how medical care can be optimized during the pandemic, what patients should do to lower their risk of getting infected with SARS-CoV-2 and what they should do if they develop COVID-19. The guidance is intended to be a living document that will be updated by the TF as data emerge.
Capsule Summary The NPF COVID-19 Task Force produced 22 guidance statements to promote optimal management of psoriatic disease during the pandemic. Shared decision making is recommended as is adherence to evidence-based recommendations when available. The guidance statements will be updated when necessary in accordance with rapidly evolving science of COVID-19.
Databáze: OpenAIRE
Externí odkaz: